Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients
- 31 July 2007
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (12) , 1561-1568
- https://doi.org/10.1097/qad.0b013e3282170a9d
Abstract
To assess risks factors and outcomes associated with nevirapine hypersensitivity reactions, and to determine the effect of hypersensitivity as a modifier of the association between hepatitis C virus (HCV) infection and mortality among antiretroviral drug-naive patients.The primary endpoint was hypersensitivity reactions in a population-based cohort of antiretroviral therapy-naive HIV-individuals, 18 years or older in British Columbia, Canada, who started triple antiretroviral therapy with nevirapine between May 1997 and June 2003. Univariate and multivariate analyses were performed to identify predictors of nonaccidental mortality in the subgroup of patients with known HCV serostatus.A total of 66 (9.6%) of 685 patients met the definition for hypersensitivity reactions. In the univariate logistic regression analysis, no variables were identified as risk factors. In multivariate survival analyses conducted to identify characteristics associated with nonaccidental mortality, patients with both HCV coinfection and hypersensitivity reactions had a higher risk of death (hazard ratio, 7.12; 95% confidence interval, 2.73-18.53; P < 0.001) compared with those who did not have HCV coinfection or hypersensitivity reaction.Results of this study suggest that the hypersensitivity reaction behaves as an effect modifier of the association between HCV infection and mortality in this cohort of antiretroviral drug-naive HIV-positive patients. These results support the current recommendation against the use of nevirapine in HIV/HCV-coinfected patients.Keywords
This publication has 25 references indexed in Scilit:
- Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentAntiviral Chemistry and Chemotherapy, 2004
- Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase InhibitorsClinical Infectious Diseases, 2004
- Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2003
- A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*JAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Efficacy and Durability of Nevirapine in Antiretroviral-Experienced PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profileAIDS, 2001
- Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysisAIDS, 2001
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- High‐Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1‐Infected Persons Does Not Result in Sustained Suppression of Viral ReplicationThe Journal of Infectious Diseases, 1997
- Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical useExpert Opinion on Investigational Drugs, 1996